$ARX

RADKE JEFFREY L sold $1.0M of ARX (indirect holdings)

RADKE JEFFREY L (Co-Founder, CEO) sold 80,000 indirectly-held shares of Accelerant Holdings (ARX) at $13.11 ($1.05M total) on 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RADKE JEFFREY L
Published Jun 26, 2026, 1:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARX
Neutral
medium confidence
Mentioned
$ARX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARXNeutralLow
01

Why it matters

The newest concrete fact is the CEO/co-founder’s open-market sale of 80,000 shares at $13.1076/share (~$1.05M) on 2026-06-23, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor ARX for continued scheduled insider selling, but the 10b5-1 designation generally limits bearish interpretation.

03

What to watch

The filing does not disclose motivations beyond the plan; traders should check whether there are multiple concurrent 10b5-1 sales or whether this sale is part of a larger scheduled tranche.

Relevance 5/10Novelty 6/10Timing: after-hours / latest SEC Form 4 filing (filed 2026-06-25)

Background

The article is an SEC Form 4 insider transaction disclosure for Accelerant Holdings (ARX).

Company-level read

Ticker impact

$ARXNeutralMedium confidence
Context

SEC Form 4 shows co-founder/CEO Jeffrey L. Radke sold 80,000 shares of Accelerant Holdings (ARX) for ~$1.05M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless follow-on selling continues.

Evidence & confidence

The filing is a primary-source insider transaction with disclosed size (~$1.05M) and confirms it was executed under a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; traders could treat it as routine rather than bearish.

Key entities

  • Accelerant Holdings

    Subject of the Form 4 insider transaction; co-founder/CEO sold shares under a 10b5-1 plan.

  • RADKE JEFFREY L

    Co-Founder, CEO, and 10% owner; reported open-market sale of 80,000 shares (indirect holdings) on 2026-06-23.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARXHighAI 9/10

Why Is Accelerant Going Private Just One Year After Its IPO?

Accelerant Holdings (ARX) agreed to be acquired by Thoma Bravo in an all-cash deal valuing it at over $4 billion, about a year after its July 2025 IPO. ARX shares rose nearly 44% on Aug. 13, 2026. Class A and B holders receive $20.25 per share. Q2 2026 revenue was $356.9 million (+62.9% YoY) and net income $80 million.

$ARXHighAI 9/10

Accelerant Holdings (ARX) Soars 57% as Buyer Bets Big on Firm

Accelerant Holdings (NYSE:ARX) shares rose about 57% after Thoma Bravo agreed to acquire the company for $4 billion. The offer price is $20.25 per share, a 49% premium to the prior close. ARX said shareholders may receive a 6% annual ticking fee if regulatory approvals delay closing, expected in H1.

$ARXHighAI 9/10

Accelerant Holdings Agrees to Thoma Bravo Take-Private Merger

Accelerant Holdings (ARX) agreed to a take-private merger with Cherry Tree BidCo, affiliated with Thoma Bravo’s Discover Fund V. If completed, ARX shareholders will receive $20.25 per share plus a ticking amount, and ARX will be delisted. The deal needs two-thirds approval and regulatory clearances, with ACP holding about 82% voting rights to support it.